This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Van Dyke, R B Articles by Murphy-Corb, M Search for Related Content PubMed PubMed Citation Articles by Van Dyke, R B Articles by Murphy-Corb, M

 Previous Article  |  Next Article 

J Clin Microbiol. 1989 August; 27(8): 1739-1743

Detection of respiratory syncytial virus in nasopharyngeal secretions by DNA-RNA hybridization.

Department of Pediatrics, Tulane University, New Orleans, Louisiana 70112.

ABSTRACT

We have developed an RNA-cDNA hybridization assay for the detection of respiratory syncytial virus (RSV) RNA in nasopharyngeal samples. We chose to use as probe a cDNA complementary to the nucleocapsid protein gene of RSV, integrated into the plasmid vector pBR322. The lower limit of sensitivity of the assay is 8.2 X 10(2) PFU of the Long strain of RSV. In throat washes with added cell-free virus, the assay can detect 3.3 X 10(3) PFU of RSV. Respiratory secretions were collected from a group of 104 infants in New Orleans, and 73 of the samples were tested for RSV by immunofluorescence (IF). All were then frozen at -70 degrees C for later testing by hybridization, and 67 were tested for RSV antigens by enzyme immunoassay (EIA). A second set of respiratory secretions from 48 infants in Denver were cultured for virus, assayed for RSV antigen by EIA, and then frozen for later testing by hybridization. For those samples on which IF was performed, hybridization, compared with IF, had a sensitivity of 49% and a specificity of 66%. For samples tested by EIA, hybridization had a sensitivity of 60% and a specificity of 81% compared with EIA. Compared with virus isolation, hybridization assay had a sensitivity of 73% and a specificity of 92%. With clinical samples, the sensitivity and specificity of the assay were improved with the addition of a control blot, which was hybridized to the plasmid vector (pBR322). The performance of the hybridization assay can be expected to improve when the assay is used with fresh clinical material rather than frozen samples.